![]() ![]() Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.Īll problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.Ĭommissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. This guidance replaces NICE medtech innovation briefing on Mepilex Border dressings for preventing pressure ulcers (MIB124). The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. This case is reviewed against the evidence submitted and expert advice. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. How we develop NICE medical technologies guidance ![]() To register as a stakeholder, please contact us at Guidance development process In April 2022, NICE started the review of this guidance. + Shipping costs (include VAT for deliveries within Germany and in EU member states incl.Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers. Im Gegensatz zum AVP ist die gebräuchliche UVP eine Empfehlung der Hersteller. bei Kindern unter 12 Jahren) das Produkt mit der gesetzlichen Krankenversicherung abrechnet. Der AVP ist ein von den Apotheken selbst in Ansatz gebrachter Preis für rezeptfreie Arzneimittel, der in der Höhe dem für Apotheken verbindlichen Arzneimittel Abgabepreis entspricht, zu dem eine Apotheke in bestimmten Fällen (z.B. Der AVP ist keine unverbindliche Preisempfehlung der Hersteller. ¹ Manufacturer's suggested retail price ( MSRP ) * Savings potential compared to the manufacturer's recommended retail price (RRP) or non-binding manufacturer's declaration of the pharmacy sales price (AVP) to the information center for proprietary medicinal products (IFA GmbH) / only for over-the-counter products except books. For medicines: For risks and side effects, read the package leaflet and consult your doctor or pharmacist.įor veterinary medicinal products: For risks and side effects, read the package leaflet and consult your veterinarian or pharmacist. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |